Management of inpatient chimeric antigen receptor T-cell therapy for relapsed/refractory B-cell malignancies: an analysis using the Japanese Diagnosis Procedure Combination database
Analysis examines perioperative management and adverse events in patients receiving CAR-T therapy, indicating vital treatment strategies.
Key Points
Treatment intensity was escalated in 2.8% of large B-cell lymphoma patients and 7% of B-cell acute lymphoblastic leukemia patients.
Tocilizumab was administered for cytokine release syndrome in 56.1% of large B-cell lymphoma patients and 42.1% of B-cell acute lymphoblastic leukemia patients.
This study utilized the Japanese Diagnosis Procedure Combination database to analyze management of CAR-T therapy in 388 patients.
Prophylaxis for fungal infections was implemented during CAR-T infusion in most patients with large B-cell lymphoma and B-cell acute lymphoblastic leukemia.